Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pioglitazone for Hepatic Steatosis in HIV/HCV Co-infection
NCT00742326Phase 4Terminated
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Aug 2008
- Primary completion
- Jan 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in hepatic steatosis comparing Pioglitazone with Placebo (2 arms). Primary endpoints: Change in Hepatic Steatosis at 48 weeks and Change in Hepatic Inflammation and Fibrosis at 48 weeks. Started Aug 2008; status: terminated.
02
Drugs
pioglitazone
03
Conditions
hepatic steatosis
Beyond the preview
Go deeper on NCT00742326.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00742326.